PPARG and Parkinson disease: Such nuclear receptors have long been involved in the control of neuroinflammatory responses [13], whereas specific non-cannabinoid PPARγ activators (e.g., thiazolidinediones) have been found to be active in experimental models of PD and have entered recently in clinical investigation [14].